eli lilly mounjaro - Search News

News

Eli Lilly weight loss pill shows promise

New Weight Loss Pill From Eli Lilly Shows Promise in Early Study

FRIDAY, Aug. 8, 2025 (HealthDay News) — A new weight loss pill made by Eli Lilly helped people lose a significant amount of weight in a recent study. Taken at the highest dose, orforglipron helped patients lose an average 27.3 pounds, or 12.4% of their body weight, over 72 weeks.

The Indianapolis Star · 21m

Eli Lilly closer to breakthrough weight loss drug; shares tumble as some question results

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial saw people lose 12% of body weight.

CBS News on MSN · 16h

Eli Lilly weight loss pill shows promise in latest clinical trial, company says

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.

Eli Lilly, Novo Nordisk and obesity

Fast Company · 21h

Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors remain unconvinced.

The Financial Times · 1d

Eli Lilly obesity pill disappoints and gives boost to arch-rival Novo Nordisk

Shares in US-based Lilly fell 14.2 per cent on the trial results, while stock in Danish arch-rival Novo Nordisk, the maker of the pioneering Ozempic weight-loss drug, rose 6.7 per cent. Novo Nordisk has been losing share to Lilly in the US in injectable weight-loss drugs.

CNBC on MSN · 1d

Eli Lilly shares drop after obesity pill shows modest late-stage trial results

Eli Lilly's pill, orforglipron, is one step closer to becoming the first new, needle-free alternative in the booming market for weight loss and diabetes drugs.

Eli Lilly: 50% Upside For LLY Stock?

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

36mon MSN

Does This $856 Million Investment Make Eli Lilly Stock a Buy?

In May, it announced it would acquire SiteOne Therapeutics, a drugmaker with a promising investigational medicine for pain.

Eli Lilly Q2 Preview: Can Mounjaro and Zepbound Keep Delivering?

Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

23hon MSN

Eli Lilly’s Mounjaro Shows Cardiovascular Benefits in Head-to-Head Trial

Eli Lilly and Company (NYSE:LLY) is one of the most profitable growth stocks to buy according to billionaires. On August 1, ...

1don MSN

Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs. The company also released long-awaited ...

1don MSN

Eli Lilly Q2 earnings beat expectations on Mounjaro, Zepbound sales, stock falls after obesity drug trial miss

Eli Lilly's Q2 earnings soared, fueled by Mounjaro and Zepbound's impressive sales, leading to raised full-year guidance.

1don MSN

Wegovy, Mounjaro sales in India double on month in July

Sales of Danish drugmaker Novo Nordisk 's Wegovy and U.S. rival Eli Lilly's Mounjaro in India doubled in July from a month ...

8don MSN

Eli Lilly's Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity

Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results